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Abstract
OPTIMIZATION OF IN VITRO TRANSCRIPTION/TRANSLATION CONDITIONS FOR
IN VITRO COMPARTMENTALIZATION STUDIES AND SYNTHESIS OF 4FLUOROHISTIDINE

By Christine Ring, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Major Director: T. Ashton Cropp, Ph.D., Associate Professor
Department of Chemistry
Genetic code expansion allows the incorporation of non-canonical amino acids with a
variety of new functional groups: fluorescent amino acids, 1-3 azides,4-6 alkynes,5-10 and
photocrosslinkers.4,11,12 This incorporation requires the evolution of new tRNA/aminoacyl
tRNA sythetase pairs.

Traditionally screenings of novel tRNA/aminoacyl tRNA

synthetase pairs have been done in vivo. While these in vivo screenings have proven
robust, they are limited in multiple ways: non-canonical amino acids (ncAAs) must be
nontoxic and bioavailable.

Furthermore, library size is limited by transformation

efficiency. Lastly, in vivo screenings require substantial amounts of the target ncAA,
which is often not available in large masses. In vitro screenings bypass these limitations:
toxicity and bioavailibilty are no longer concerns. Library size can be expanded by several
orders of magnitude as we are no longer limited by transformation efficiency. Lastly,
because in vitro transcription/translation reactions are routinely conducted on the μL
scale, ncAA usage can be minimized. We set out to use in vitro compartmentalization to
further expand the code. In an in vitro compartmentalization screening, the water droplets
in a water-in-oil emulsion serve as separate reaction chambers in which individual library

xii

members are transcribed and translated.
transcription/translation reactions.

Here we report optimization of S30

Optimizations include cell lysis method, reaction

temperature, template amount, and T7 RNA polymerase amounts. Yields remained low
and we transistioned into the use of PURExpress.
Fluorohistidines are isosteric with histidine, but not isoelectronic. 13

This change in

environment results in a reduction of pKa. We set out to synthesize 4-fluorohistidine to
use as a pH probe in several target proteins.

A synthesis of 4-fluorohistidine was

published in 1973.14,15 We were able to improve upon this synthesis by reducing cost and
improving yield of a key step in the reaction. Next, small peptides with polyhistidine tags
were translated in vitro using our 4-fluorohistidine. We are calling this polyhistidine tag
incorporating 4-fluorohistidine our “hexafluorohistag.” Because of the reduced pK a of the
4-fluorohistidine, the hexafluorohistag showed affinity to Nickel-NTA resin even at
reduced pH. This allowed for the purification of hexafluorohistagged peptides in the
presence of traditional polyhistidine-tagged peptides.
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Chapter 1: Introduction
The ability to genetically encode unnatural or non-canonical amino acids (uAAs or ncAAs)
into peptides allows researchers to incorporate photocrosslinkers,4,12,16 introduce new
functional groups such as alkynes5-10 or azides4-6 into proteins, and to introduce
fluorescent residues to proteins.1-3 This incorporation is accomplished through sitedirected mutagenesis at the nucleic acid level and stop codon suppression at the
translational level.
Site-directed mutagenesis uses the technique of polymerase chain reaction (PCR) to
incorporate desired mutations into a DNA template during the amplification of that
template. In PCR, a double-stranded DNA is first denatured at high heat, separating the
two strands of DNA. Upon cooling, the DNA will anneal to complementary DNA. This
complementary DNA can be the other strand of template, or – in the case of PCR – it can
come in the form of short single-stranded sequences of DNA. We call these short
sequences primers. Primers are engineered to be perfect complements to the DNA
template. When the DNA template anneals to the primer, there is now a gap that must
be filled in.

DNA polymerases supplied to the reaction mixture will fill in this gap,

amplifying the DNA template. In site-directed mutagenesis, primers are designed to
contain small mutations. The DNA template can still anneal to the rest of the primer and
when the polymerase extends the sequence, the new amplification product includes the
mutation. Incorporation of a stop codon into a primer sequence allows for one to take
advantage of a powerful technique for the incorporation of ncAAs: stop codon
suppression.
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In 1989, the Schultz group described the use of stop codon suppression to
biosynthetically incorporate ncAAs into proteins in in vitro translation conditions.17 In stop
codon suppression, a stop codon – for this work the amber stop codon, TAG - is inserted
into the DNA sequence that encodes a protein using site-directed mutagenesis as
described above. Next the organism needs to be transformed with DNA encoding an
orthogonal pair of transfer RNA (tRNA) and aminoacyl tRNA synthetase (aaRS).
Aminoacyl tRNA synthetases are enzymes responsible for the loading, or charging, of
amino acids onto tRNA. Once charged with its amino acid payload, the tRNA is free to
base-pair with messenger RNA (mRNA) at the ribosome. In this way the amino acid is
able to be incorporated into the growing peptide. An orthogonal pair of tRNA-aaRS is a
pair that works with each other but does not disrupt other cellular processes. (Figure 1)
For instance, an orthogonal aaRS must be able to charge its cognate tRNA with target
amino acid but must not also charge endogenous tRNA. Likewise, the orthogonal tRNA
must not be charged by endogenous aaRS. Because the orthogonal tRNA will have the
anticodon which corresponds to a stop codon incorporated into its anticodon loop, the
result of this pair will be the insertion of an amino acid at a stop codon. Thus, this pair
suppresses the ability of a stop codon to stop protein expression. For this work, as we
are using the Amber stop codon – TAG –, the orthogonal tRNA anticodon loop must
contain the reverse complement, CUA.

2

Figure 1. An orthogonal tRNA-aaRS pair work together but do
not work with other tRNA, aaRS, or amino acids. Endogenous
tRNA and aaRS are shown in orange. Orthogonal pair are
shown in green. As seen, the orthogonal tRNA can be charged
with its cognate aaRS, but not the endogenous aaRS.
Likewise, the orthogonal aaRS cannot charge the endogenous
tRNA.

3

A useful class of ncAAs is fluorescent amino acids. Previous methods of fluorescently
labeling proteins took two forms: formation of a fusion protein with a fluorescent protein
or labeling the protein after translation. While the incorporation of fluorescent proteins
such as green fluorescent protein (GFP) allows for the monitoring of proteins via
fluorescence, these fluorescent proteins are of substantial size (>20 kD).2 This large size
limits spatial detection and can interfere with protein function. 2 Labeling proteins after
translation requires an extra step after translation: the labeling. When done in vivo this
labeling step requires cell-permeable reagents and can alter protein function.2 In vitro
techniques are available, but are limited in scale. 2 Two examples of fluorescent ncAAs,
dansylalanine, 1, and (7-hydroxycoumarin-4-yl)-ethylglycine, 2, can be seen in Figure 2.
Both were incorporated by the Schultz group and reported in 2006.1,2 Dansylalanine was
incorporated into human superoxide dismutase (hSOD), a protein involved in oxygen
metabolism.2 Once incorporated, the fluorescent signature of the dansyl alanine was
measured over various salt concentrations, allowing the real-time monitoring of protein
unfolding.2 (7-hydroxycoumarin-4-yl)-ethylglycine was incorporated into myoglobin and
was similarly used as a probe of unfolding in the presence of urea.1

4

Figure 2. Fluorescent amino acids.
examples of fluorescent amino acids.

Two

Another class of ncAAs which have been synthesized and incorporated into proteins is
the photocrosslinker.4,11,18 These amino acids contain functional groups which, upon
irradiation, form covalent bonds with nearby molecules. 4,11,18 These photocrosslinkers
have shown valuable in covalently capturing protein-protein interactions. Because these
protein-protein interactions are short-lived and non-covalent, determining the location
where the interaction occurs can prove challenging. By incorporating a photocrosslinking
amino acid into multiple sites of one of the binding partners, the locus of interaction can
be determined. (Figure 3B,C) Two examples of photocrosslinking amino acids can be
seen in Figure 3A. The first of these examples, para benzoylphenylalanine, was first
incorporated into a protein in 198611 by solid-state protein synthesis. By incorporating
this photocrosslinker into a known binder of calmodulin, the binding of this binder and
calmodulin was captured. The second example, 4’-(3-(trifluoromethyl)-3H-diazarin-3-yl)
phenylalanine, was described in 1988.19 Both para benzoylphenylalanine and 4’-(3-

5

trifluoromethyl)-3H-diazarin-3-yl)-phenylalanine were later genetically encoded into
proteins20,21, allowing for both in vivo use and less time-consuming protein production.

Figure 3. Photocrosslinking amino acids shed light on protein-protein interactions. a.
The structures of two photocrosslinking amino acids. b. Two binding partners are
represented, but it is unknown where on each protein the interaction occurs. c. A
photocrosslinker (PC) has been inserted in differing locations on one of the binding
partners. After incubating each of these mutants with the other binding partner,
irradiation occurs only in the example where the photocrosslinker is incorporated at
the location of interaction.

Another class of ncAA which can be incorporated is amino acids which mimic the effects
of post-translational modifications (PTMs). PTMs are functional groups which are added
to a protein after it is translated. Some common PTMs are methylation,22-27 acetylation,2729

glycosylation,27,30-32 and ubiquitination.27,33-35 In order to investigate the effects of post-

translational modification at specific sites, it is ideal to express proteins with the
modification genetically encoded in the form of a non-canonical amino acid. Unfortunately
simply expressing the protein and then allowing it to become enzymatically modified
results in a mixture of products, including singly-modified proteins as well as multiply6

modified proteins. (Figure 4) Two examples of ncAAs which incorporate the functional
groups of post-translational modifications can be seen in Figure 5.

By genetically

encoding N-ε-acetyl lysine into several positions in histone H3, the Chin group was able
to determine the effect of lysine acetylation in a site-specific manner.36

Figure 4. Post-translational modification results in a mixture of modified peptides.
Allowing a protein to become enzymatically acetylated results in multiple acetylated
products

7

Figure 5. ncAAs can mimic posttranslational modifications.
N-εacetyl lysine and N-ε-butyryl lysine
are ncAAs which mimic a
modification that typically occurs
post-translationally.
ncAAs containing protecting groups can also be incorporated into proteins.

This

technique is useful when planning to do further chemical modification of a protein after it
is expressed. One such example of an amino acid that contains a protecting group is
Boc-lys (figure 6). Previous work in our group37 used this Boc-lys to protect a selected
lysine residue on a peptide containing multiple lysine residues. By protecting one residue,
reactions of the ε-amino group of the remaining lysine residues were able to be performed
without affecting the protected residue.

8

Figure
6.
BocLysine
incorporates a Boc protecting
group onto the side chain of
lysine.
Finally, amino acids with functional groups that participate in biorthogonal click
chemistry4-10 can be incorporated into proteins. These amino acids contain functional
groups such as azides4-6 and alkynes5-10 which are not naturally present in the cell.6
These functional groups meet the requirements of biorthogonality: they must not react
with other biological molecules, they must be non-toxic, and they must react quickly and
selectively with each other.6 One potential application of this technology is cell labeling.6
Incorporation of an azide ncAA into membrane-bound proteins allows for the labeling of
these cells when incubated with a fluorescent dye bound to an alkyne moiety (Figure 7).6

9

Figure 7. Click chemistry for live-cell labeling. Incorporation of an azide ncAA into
membrane-bound protein allows for the labeling of cells with alkyne-containing
molecules

10

Chapter 2: Optimization of in vitro transcription/translation conditions for in vitro
compartmentalization studies
While all of the amino acids shown in the previous chapter are valuable tools for
researchers, the addition of further ncAAs to the genetic code is of course desirable. In
particular, we were interested in the ability to genetically encode post-translational
modification amino acids which had not already been encoded, specifically glycosylated
amino acids.

These amino acids have not been genetically encoded previously.

Glycosylated protein residues on membrane-bound proteins are implicated in the ability
of the Streptococcus genus to adhere to host tissues,38-42 increasing their pathogenicity.
As such, these glycoproteins are possible drug targets for the treatment of bacterial
infections.38 The addition of saccharides and polysaccharides to an amino acid results in
a residue that is not only much larger than the unmodified amino acid, but also more polar
as the sugars contain multiple hydroxyl groups. Two amino acids which are frequently
targeted in bacterial glycosylation are serine and threonine. 38-42

Because of the

importance of these glycosylations in bacterial infections, we wanted to evolve new
synthetases for the genetic incorporation of glycosylated serines and threonines.
In this project, we set out to evolve novel mutants of the pyrrolysl tRNA synthetase
(PylRS) using in vitro compartmentalization. In methanogens such as Methanosarcera
barkeri, the amino acid pyrrolysine is inserted into proteins using the tRNA-aminoacyl
tRNA synthetase pair, pylT and pylS43,44, This pair recognizes the amber UAG codon as
a sense codon, rather than as a stop codon. This system has been used to insert
pyrrolysine and other lysine analogs at stop codons.43-58
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Evolution of novel tRNA-tRNA sythetase pairs is traditionally done in vivo. A schematic
of the workflow of this process can be seen in Figure 8. Before selection can begin, a
library of DNA mutants must be created. This is done by first selecting amino acids in
the binding pocket of an existing aminoacyl tRNA synthetase that interact with the existing
substrate amino acid (figure 9).

Cotransform selection
plasmid and library of
DNA mutants into cells

Incubate
16 hours

2 hours

Pick colonies which grew
and plate onto media
containing 5-fluorouracil
and no ncAA

In vivo selection
35 hours

Plate onto media
containing
chloramphenicol, 20
naturally-occurring amino
acids, and the ncAA
30 minutes

30 minutes

Incubate
16 hours

Figure 8. The work flow of one round of in vivo selection is shown. In the positive
selection, library members which suppress stop codons by inserting either the ncAA
of interest or one of the 20 canonical amino acids will produce cells capable of growth.
In the negative selection, stop codon suppression results in the expression of a toxic
gene. In this selection the cells are supplied with only the 20 canonical amino acids.
Library members which encoded endogenous suppressors will express the toxic gene
and die. One round of selection takes a minimum of 35 hours.
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Figure 9. The binding pocket of M. mazei PylRS with pyrrolysine (pdb code 2Q7H).
Amino acid residues which interact with pyrrolysine are highlighted: the asparagine at
position 346, the cysteine at position 348, the valine at position 401, and the glycine
at position 421.

Randomization of the selected amino acids by site-directed mutagenesis generates a
library of DNA mutants. Because there are twenty naturally-occurring amino acids, library
size increases rapidly with the number of selected amino acid residues; 5 mutations result
in a library size of 205, or 3.2 million library members.

Increasing the library by

randomizing six residues generates 64 million library members and seven randomized
13

residues results in 1.28 x 109 library members. Next, the DNA library is screened using
a double-sieve selection process (figure 10). In this process, the DNA library is first
transformed into cells which have a selectable marker such as chloramphenicol
acetyltransferase, a gene responsible for conferring resistance to the antibiotic
chloramphenicol. These cells, each of which now contain both the selectable marker and
the library member, are grown on plates which contain both the ncAA of interest and
chloramphenicol. In order for cells to grow in under these conditions, read-through at the
stop codon on the selectable marker must occur. Thus any cells which grow at this stage
contained the ability to read through a stop codon by either inserting the ncAA contained
in the growth media or any of the 20 naturally-occurring amino acids which were also
present. The next step of the selection process is to remove the false positives from the
previous selection step. In this step the selectable marker is a gene which encodes a
toxic protein, such as uracil phosphoribotransferase (UPP). Library members which
survived the first selection are transformed into cells containing the selectable marker and
then grown on plates which do not contain the ncAA of interest. Cells which grow in this
step must not be able to suppress the stop codon, meaning that they do not insert any of
the 20 naturally-occurring amino acids. The false positives from the first selection step
will still be able to suppress the stop codon, thus generating the toxic protein.

14

Figure 10. Simple schematic of a double-sieve selection process. A library containing
non-functional aaRS (blue circles), aaRS which insert naturally-occurring amino acids
(red circles), and aaRS which incorporate the target ncAA (green circles) are screened.
The first step of the selection results in a library of aaRS mutants which incorporate
any of the amino acids present. The second step of the selection removes the aaRS
mutants which incorporate the 20 naturally-occurring amino acids.

There are several drawbacks to an in vivo approach: first, in vivo studies require the
growth of bacterial cultures for each library member screened. This is not only timeconsuming but each selection cycle will consume a minimum of 500 mg of the chosen
ncAA. When using a difficult-to-synthesize or expensive ncAA, this may make a study
either impossible or cost prohibitive. This also means that toxic amino acids cannot be
used in traditional in vivo methods. Second, library sizes are limited by transformation
efficiency, so the maximum library size is in the range of 10 8 library members. Third, in
vivo studies are confined to the use of amino acids which are bioavailable in the cell.
ncAAs which cannot cross the cell membrane are eliminated, as are ncAAs which are
actively transported out of the cell. In addition, the metabolism of certain ncAAs can lead
to a reduced effective concentration in the cytosol and thus require increased amounts of
ncAA to achieve sufficient intracellular concentration.
In vitro techniques are ideal for evolution studies. By circumventing the need to transform
large libraries into cells and grow cultures, they overcome several of the limitations of in
15

vivo studies. First, library size is no longer limited by transformation efficiency, as there
is no transformation step; library size can be several orders of magnitude larger than in
in vivo selections. These methods also allow for much smaller-scale protein synthesis; in
vitro transcription/translation reactions are routinely run on the 10 μL scale. This allows
for much more economical ncAA usage, which is key with scarce ncAAs. Because we
are no longer working in cells, bioavailability is no longer a concern. There is no cell
membrane to cross, no active transport across a cell membrane, or cellular metabolism
with which to be concerned. Because toxicity is also not a concern in these studies,
expression of potentially-toxic proteins is possible in vitro as is the incorporation of toxic
amino acids.

For this same reason, selection conditions (pH, temperature, ion

concentrations, unnatural amino acid concentrations, etc.) can be manipulated more
widely than in in vivo approaches.
One of the great advantages of in vivo studies is that genotype and phenotype are
automatically linked spatially; the DNA which encodes a given protein will be enclosed
within the same cellular membrane that also holds that expressed protein. Any in vitro
screening must mimic this spatial link if there is to be any hope of multiple rounds of
amplification and selection.

Many in vitro screens attempt to mimic this cellular

compartmentalization through the use of microwell plates. While the walls of the well do
effectively contain both the DNA and the protein of interest, this is a resource- and timeconsuming method; routine screenings using this method use libraries between 10 5-107.
This is also more resource-intensive, as the volume of the wells of even a microtitre plate
is 109 larger than an E. coli cell.59 Because of this, one would need one hundred thousand
1536-well plates to replicate the number of compartments present in on milliliter of E. coli
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cells59. In 1998, Tawfik and Griffiths described a new compartmentalization technique, in
vitro compartmentalization,60 IVC. This technique utilizes a water-in-oil emulsion to create
small aqueous compartments in which chemistry occurs. By carefully controlling reagent
concentrations, they showed that one could have an average of one piece of DNA in each
compartment, so that any protein translated by that DNA would be contained in the same
water droplet. Using this technique, it has been shown that 1010 droplets can be produced
in one milliliter of water-in-oil emulsion; thus libraries of 1010 members can be screened
in one microcentrifuge tube.60
We proposed using IVC to evolve new aminoacyl tRNA synthetases. In order to do this,
we needed to design a system in which stop codon suppressors would result in a fullyformed protein which could be separated through affinity chromatography (Figure 11).
We chose to include a polyhistidine tag on our protein for several reasons: the addition of
the polyhistidine tag to the DNA template was readily accessible through primer design,
the nickel-NTA resin used for this purification is inexpensive and reusable, and this
purification method is readily adaptable to use in a batch purification method. Nickel-NTA
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purification cannot however be performed using the emulsion conditions of IVC.

Figure 11. Stop codon suppression and affinity chromatography. Stop codon
suppression used in in vitro library screening allows for use of affinity chromatography
to separate full-length translational products from truncated products. Here we show
the incorporation of a polyhistidine tag for use with Ni-NTA resin.
Because this purification step necessitated breaking the emulsion of in vitro
compartmentalization before screening our library members, it was necessary to
covalently bond our DNA mutant library members with any protein produced inside the
water droplets of the in vitro transcription/translation. In our studies, we use the SNAPtag protein to form the genotype-phenotype linkage. SNAP-tag, an analogue of O6alkylguanine-DNA alkytransferase,61 has an exposed sulfur. Inside the binding site of the
enzyme, the sulfur performs a nucleophilic attack on its substrate, benzyl guanine-labeled
DNA, creating a covalent bond between the SNAP-tag protein and the DNA which
encodes it. (Figure 12) When the SNAP-tag protein is expressed as part of a fusion
protein, the entire fusion protein becomes covalently bound to the DNA which encoded it;
thus a true covalent genotype-phenotype linkage is created. Because this is a true
covalent linkage, it is durable under a variety of conditions (non-physiological pH,
temperature, and ion concentrations).
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Figure 12. The creation of a genotype-phenotype
linkage between the SNAP-tag protein and benzyl
guanine-labeled DNA.

Recently the Ellington group out of the University of Texas at Austin has published work
with a very similar goal of ours, also using water-in-oil emulsions to direct evolution of
orthogonal tRNA synthetases and orthogonal tRNAs.62 While at first glance this paper
appears to have achieved our goals, a closer read reveals that there are some key
differences between what the Ellington group has done, Compartmentalized Partnered
Replication (CPR), and our group’s eventual goals with this project.
First, a library of gene circuits is transformed into E. coli, so this technique is not a purely
in vitro technique. These gene circuits contain two important ORFs: those for Taq
polymerase and for a partner gene. The partner gene in which we are primarily interested
is that of a tRNA synthetase. Next, the E. coli is allowed to grow and expression of this
region is induced. Should the synthetase of a particular library member be functional,
Taq polymerase will be expressed. Should a particular synthetase be nonfunctioning,
then Taq polymerase will not be expressed. After expression is complete, the culture is
emulsified so that each aqueous compartment contains one cell.
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The emulsion

undergoes thermal cycling which both lyses the cells and amplifies the DNA in each
compartment. After several rounds of selection only the most active synthetases are
present in the reaction mixture.
While this technique has definitely been shown effective, there are some drawbacks.
Because this technique relies on an in vivo expression it is susceptible to the requirements
of in vivo studies (e.g. limited library size, amino acids must be bioavailable, proteins
expressed cannot be toxic, etc.). Second, there is no true genotype-phenotype linkage.
While this technique does effectively identify active synthetases the synthetase is not
linked to the polymerase which it created. In any such study one would expect to find
variations in not only the activity of these synthetases but also in their accuracy. Because
this technique does not covalently link the DNA to its encoded proteins assessment of the
quality of the Taq polymerase created must be done in separate experiments.
Like the in vivo selections described above, the in vitro process we proposed would also
have a double-sieve selection process (Figures 13,14). In the first round of selection, a
DNA library would be mixed with an in vitro transcription/translation system containing all
20 naturally-occurring amino acids and the ncAA of interest for the study. As in the in
vivo selection, library members that are able to suppress a stop codon would produce full
length protein. Rather than using the selectable marker of antibiotic resistance however,
our chosen selectable marker was a polyhistidine affinity tag.

This allows for the

purification of positive hits from non-functional synthetases by nickel resin affinity
chromatography. (Figure 12) The protein (bound to its template) is eluted and the DNA
templates are amplified by PCR.

In the next round of selection, the in vitro

compartmentalization is performed in the absence of ncAA. Now only the templates
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which encode non-target aminoacyl tRNA synthetases produce functional protein which
is retained on the nickel resin target. The desired library members flow through the
column and are collected.

Set up IVC with cellfree translation
mixture, library of
DNA mutants, and
ncAA

Nickel resin
purification
30 minutes

20 minutes

Incubate

Incubate

2 hours

2 hours

In vitro selection
7 hours 40 minutes

Set up IVC with cellfree translation
mixture, amplified
DNA, and no ncAA

Nickel resin
purification
30 minutes

20 minutes

Amplify DNA from
nickel resin elution
2 hours

Figure 13. The work flow of one round of selection with our in vitro approach. Here,
one round of selection takes approximately 8 hours as compared with the in vivo
approach (seen in Figure 8) which requires at least 35 hours
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Figure 14.
Schematic of one selection cycle of our proposed in vitro
compartmentalization studies. In the first round of selection, DNA templates which
encode functional aminoacyl tRNA synthetases produce proteins which adhere to the
nickel resin column. These templates are PCR-amplified and then the in vitro
compartmentalization step is repeated in the absence of ncAA. In this second round,
templates which encode functional aminoacyl tRNA synthetases by incorporating nontarget AAs adhere to the column and the desired library members remain in the flowthrough. The library members collected in this flow-through can be subjected to further
rounds of selection.

The advantages of an in vitro selection system are summarized in table 1. Because of
the larger theoretical library size, suitability for use with toxic or non-bioavailable amino
acids, and shorter selection cycle, we decided to move forward with this in vitro approach.
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ncAA usage

In vivo selections

In vitro selections

At least 500 mg/selection

<1 mg per selection cycle

cycle
Time per cycle

At least 35 hours

8 hours

Library size

105-108

Proposed work: 1010

ncAAs

Must be bioavailable and

No limitations on identity of

nontoxic

ncAA

Table 1. Comparison of the demands of an in vivo vs. in vitro selection process. The
advantages afforded by an in vitro approach include more economical ncAA usage,
shorter selection cycles, larger library sizes, and the ability to work with amino acids
which are neither bioavailable nor nontoxic.
The first steps of this project involved the creation of a fusion protein of the previously
described SNAP-tag and superfolder Green Fluorescent Protein (sfGFP). We needed
the DNA template for this protein to include both a T7 promoter (for efficient expression
of the protein) and a poly-histidine tag (for protein purification using nickel resin). sfGFP
was desirable here for two of its properties: its stability and its fluorescence. This stability
ensured that our fusion protein would be stable under a wider variety of conditions. Its
fluorescence allows for us to measure fluorescent intensity as a marker for protein
production. First, the gene encoding this protein needed to be constructed. Amplification
of both the SNAP-TAG gene and the sfGFP gene were done through polymerase chain
reactions (PCRs).

Oligonucleotides with complementary overlapping sections were

designed for these PCRs and Phusion DNA polymerase was used to ensure few
mutations in the resulting products. Next, the products of these reactions were used as
template in an overlap PCR reaction, giving the SNAPGFP gene as product. This gene
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was next cloned into the pJET1.2 vector from New England Biolabs. After transformation
into GeneHog competent cells, colonies were selected and small-scale cultures were
grown. The plasmid DNA was extracted using the Zyppy Plasmid Miniprep kit These
samples were sequenced, revealing successful incorporated the SNAP-GFP gene into
the plasmid.
Next we needed to confirm that the SNAPGFP fusion protein retained the ability to bind
to benzyl guanine-labeled substrate. To do this, we first needed to label DNA with benzyl
guanine.

Amino-labeled oligonucleotides were ordered and were allowed to react

overnight with a benzyl guanine-containing N-hydrosuccinimide (NHS) ester. To confirm
labeling, this labeled oligonucleotide was analyzed via electrospray mass spectrometry.
Once the labeling was confirmed, samples of both labeled and unlabeled DNA were
allowed to react overnight with a five-fold molar excess of the SNAP-tag/sfGFP protein.
This molar excess was chosen because in the future in vitro compartmentalization
experiments, we will have only one copy of DNA per water droplet but potentially several
copies of the protein after it has been translated. A 15% PAGE TBE/Urea gel was run,
comparing the relative sizes of the unbound oligonucleotides with the oligonucleotides
which had interacted with the SNAP-tag/sfGFP protein (Figure 15) As shown below, the
unlabeled oligonucleotide shows no binding with the SNAP-tag/sfGFP protein, whereas
the labeled oligonucleotide clearly bound to the protein.

24

A

B

C

D

Figure 15. SNAPGFP fusion protein retains SNAP-tag functionality. TBE/Urea gel of
oligonucleotides. A. Unlabeled DNA template encoding SNAPGFP protein B.
Unlabeled DNA template after incubation with SNAPGFP protein C. DNA template
labeled with benzyl guanine. Note that no purification was performed after this labeling
step, so both unlabeled and labeled DNA is observed. D. Labeled DNA template after
incubation with SNAPGFP protein. Here we see that the labeled DNA has become
attached to the SNAPGFP protein.
Having successfully created our SNAPGFP fusion protein and demonstrated the retention
of the SNAP-tag functionality, our next steps were to express this protein in vitro. When
selecting E. coli-based in vitro transcription/translation systems one must choose
between whole-cell extracts and Protein Synthesis using Recombinant Elements
(PURExpress). The preparation of whole-cell extracts is typically done in-house and is a
very inexpensive process which requires little specialized equipment. These extracts
contain both ribosomes and all soluble cellular protein from the E. coli strain used. While
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this is a cost-effective method, these soluble proteins include both nucleases and
proteases which can pose difficulties. Nucleases can digest the DNA template provided
in the reaction and proteases can digest the protein product of these translations. Another
drawback of the use of whole-cell extracts is the time taken to prepare each extract. The
alternative method considered for this work was PURExpress, a commercially available
solution that is composed of transcription and translation factors purified from E. coli.
Because only the cellular machinery necessary for transcription and translation are
included, there are no nucleases and proteases present. Another benefit to the use of
PURExpress is the elimination of the extract preparation step for this work. That said,
when beginning this work we anticipated using thousands of microliters of
transcription/translation mixture for our selections and the use of PURExpress did not
appear to be a responsible use of laboratory funds at the outset. Furthermore, we were
initially confident in our ability to reproduce the results of other work with whole-cell
extracts.
The whole-cell extract system we chose to use was the S30 extract optimized for the use
of a T7 promoter previously reported by Pratt63 and previously tested in our group.64 To
prepare these extracts, the first step was to grow large cultures of E. coli. We chose to
make our extracts using a strain in which release factor 1 (RF1) activity had been reduced
by attaching a chitin binding domain to the protein. 65 RF1 is the release factor that
recognizes the amber stop codon, leading the ribosome to release the mRNA transcript.
Because our eventual goals involved the suppression of the amber stop codon, we hoped
to see greater suppression by using this strain.
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Preparation of S30 extracts
Extract was prepared largely as in Liu, 2012.64 RF1 CB E. coli cells were grown to
OD600 of 0.8 and pelleted at 5,000xg for 10 minutes at 4º C. The cells were washed
twice with S30 buffer. The pellet was stored at -80º C overnight. To lyse the cells, the
cells were resuspended in 1 mL S30 buffer per gram of pellet. Next the cells were lysed
by sonication. The cells were sonicated on ice for five rounds of 20 minutes each with
2.5 minute rests in between rounds. The lysate was transferred to centrifugation tubes
and centrifuged for 30 minutes at 30,000xg. The cleared lysate was transferred to clean
centrifugation tubes and centrifuged again for 30 minutes at 30,000xg. Next a run-off
reaction was performed to consume endogenous mRNA. The supernatant was
transferred to a new tube and 0.2xvolume pre-incubation solution was added. The
solution was incubated at 37º C in the dark, becoming cloudy. The solution was then
transferred to dialysis tubing (MWCO 6,000-8,000) and dialyzed against 100xvolume of
S30 buffer for forty minutes at 4º C. The solution was aliquoted into 200 μL portions,
flash frozen, and stored at -80º C.
S30 buffer
10 mM Tris-acetate, pH 8.2
60 mM potassium glutamate
14 mM magnesium acetate
1 mM DTT
Pre-incubation solution
370 mM Tris-acetate, pH 8.2
11.1 mM magnesium acetate
5.5 mM DTT
16.5 mM ATP (MP Biomedicals, Solon, OH)
50 μM each of the 20 natural amino acids (Acros)
105 mM phosphoenolpyruvate (Alfa Aesar, Ward Hill, MA)
8.4 U/mL Calbiochem rabbit muscle pyruvate kinase (EMD Millipore, Rockland, MA).
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S30 transcription/translation reactions
The S30 reaction protocol was taken directly from Liu, 2012.64
The homemade S30 reaction contained 55 mM HEPES, pH 7.5, 1.7 mM DTT, 27.5
mM ammonium acetate, 208 mM potassium glutamate, 19.3 mM magnesium
acetate, 3.5 mM each of the 20 natural amino acids, 68 μM folinic acid, 1.2 mM
ATP, 0.85 mM each of GTP, CTP and UTP, 0.64 mM 3', 5'-cyclic adenosine
monophosphate (cAMP), 0.25 mg/mL of creatine phosphokinase, 80 mM creatine
phosphate, 0.17 mg/mL of E. coli total tRNA (Roche Applied Science, Indianapolis,
IN), 0.1 mg/mL T7 RNA polymerase, 25% (v:v) of cell extract and 16 μg/mL DNAs.
The reaction was incubated on a shaker at 37 ºC for 4 h. For sfGFP reporter, the
fluorescence was monitored directly after reaction.
To successfully perform this S30 reaction, the following stock solutions were
prepared and added in the order as below: 1) nuclease-free water 2) 10× reaction
buffer (550 mM HEPES, pH 7.5, 17 mM DTT, 275 mM ammonium acetate, 2.05 M
potassium glutamate, 193 mM magnesium acetate); 3) 50 mM water soluble amino
acid mix (Ala, Arg, Gly, His, Lys, Pro, Ser, Thr and Val), dissolved in water; 4) 50
mM of base soluble amino acid mix (Ile and Phe), dissolved in 1 M NaOH; 5) 50
mM of acid soluble amino acid mix (Asp, Asn, Cys, Glu, Gln, Leu, Met, Trp and
Tyr), dissolved in 1 M HCl; 6) 64 mM cAMP (100×), dissolved in water by dropwise
addition of 1 M NaOH; 7) 6.8 mM folinic acid (100×), dissolved in water; 8) NTP
mix containing 120 mM ATP and 85 mM each of GTP, CTP and UTP (100×),
dissolved in water; 9) 1.6 M creatine phosphate (20×), dissolved in water; 10) 25
mg/mL creatine phosphate kinase (100×), dissolved in water; 11) 5 mg/mL homepurified T7 RNA polymerase (50×), in storage buffer (50 mM Tris-HCl, pH 7.9, 100
mM NaCl, 20 mM 2-mercaptoethanol, 1 mM EDTA, 50% Glycerol and 0.1% Triton
X-100); 12) S30 cell extract, pre-thawed on ice (may take up to 1 h); 13) DNA
template of high quality and cocentration, dissolved in nuclease-free water; 14)
commercial or home-made E. coli total tRNA.

Protein yield was monitored via fluorescence and normalized to a standard of known
purified sfGFP concentration for all the work presented here. While we were able to
successfully prepare an S30 extract that successfully translated sfGFP from plasmid DNA
template, we discovered quickly that these S30 extracts had high batch-to-batch
inconsistency for us.
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While our first attempts at producing S30 extract were successful, later attempts using
the same protocol were unsuccessful. After exhausting attempts at remaking stock
solutions for these reactions, we next looked at our cell lysis method. Initially, we had
been using a bead beater to lyse our cells. Bead beating is a gentle method of cell lysis,
and we were attracted to this method because we did not want to denature the
transcription and translation factors we needed for the extract. We moved next to
sonication. Sonication is a more violent method of cell lysis, but we were at least able to
produce functional S30 extract using this method.
While we were plagued with this low reproducibility using these S30 extracts, we did find
that some factors remained consistent over the course of the years during which we used
these extracts. First, T7 RNA polymerase prepared in-house gave us higher yields of
protein than commercially available polymerase. (Figure 16)

800
700
600

ng sfGFP

500
400

house-made polymerase

300

NEB polymerase

200
100
0
-100

No DNA

purified sfGFP

pRSETb/sfGFP

Figure 16. Freshly-prepared T7 RNA polymerase produces greater protein yield than
commercially-available polymerase. Protein yields for a 100 μL S30 translation. We
had a 3.75-fold increase in production using freshly-prepared house-made T7 RNA
polymerase when compared with commercially-available polymerase.
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We also found that incubating these S30 transcription/translation reactions at a lower
temperature (30ºC vs. 37º C) resulted in higher protein yields. (Figure 17) Previous work
in the field66 showed that EF-Tu, EF-Ts, and ribosomal protein L9 were subject to
significant proteolysis in S30 reactions carried out at 37º C. These proteins are all
necessary for translation: EF-Tu brings charged tRNAs to the ribosome, EF-Ts helps
regenerate EF-Tu, and ribosomal protein L9 is a constituent of the ribosome.
Furthermore, reduced temperature has been shown to increase both yield and product
activity in S30 reactions conducted at lower temperatures.67
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0
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Figure 17. S30 reactions are more productive at 30º C. Protein yields of 100 μL S30
reactions incubated for 6 hours at differing temperatures. This trend of higher yield at
lower temperature held true over multiple extract preparations. Each condition was
performed in triplicate. Protein yields were measured by fluorescence and quantified
based on fluorescence of an sfGFP sample of known concentration.
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Optimization of amounts of extract added per reaction, amounts of T7 RNA polymerase,
and amounts of DNA template added were also performed, though the result was highly
batch-dependent. (Figures 18-20)

Fluorescent Intensity
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μL T7 RNA polymerase

Figure 18. Optimization of amount of T7 RNA polymerase added to each 100 μL
reaction. Fluorescent intensity of 100 μL S30 translation reactions was measured at 6
hours. Reactions were run in triplicate. Protein yield here was not quantified as no
standard was included in this measurement.
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Figure 19. Optimization of amount of DNA template. 100 μL S30 translation yields
with varying amounts of DNA template. Reactions were run in triplicate and protein
was quantified based on fluorescence relative to an sfGFP sample of known
concentration.
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Figure 20. Translation yields were compared of plasmid DNA vs. linear DNA
templates. Results are for 100 μL S30 reactions run in triplicate. Protein yield was
quantified by fluorescence relative to an sfGFP sample of known concentration. A.
Reaction with no DNA template B. Reaction mixture with no DNA template. Purified
sfGFP was added as a standard.
C. pRSETb/sfGFP translation D.
pJET1.2/SNAPGFP translation E. linear template sfGFP translation F. linear template
SNAPGFP translation
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While these optimizations did give us higher protein yields than our initial attempts, the
protein yield was still several orders of magnitude lower than yields reported in the
literature. Although we were disappointed with these low yields, high protein yield was
never the overall aim of this project; we needed only one peptide generated per
microdroplet in our in vitro compartmentalization reactions to successfully complete this
project. As the IVC selections would require transcription/translation of linear templates,
we moved forward with S30 trials using both plasmid DNA and linear DNA as templates.
(Figure 18) This trial led us to two conclusions: first, we were seeing about a ten-fold
reduction in protein yield when translating pRSETb/sfGFP vs. our linear sfGFP template.
We had expected a reduction of this sort as proteases exhibit greater activity with linear
DNA. Second, we saw that our SNAPGFP construct, pJET1.2/SNAPGFP, was not
translating as well as the other plasmid. We knew that the SNAPGFP was fluorescent so
we did not believe this to be a result of differing physical properties of the sfGFP vs.
SNAPGFP protein products. As mentioned above, we had cloned our SNAPGFP DNA
template into the pJET1.2 vector. This vector is a blunt-end vector. As such, there should
be a fifty percent chance that the insert would be incorporated in the same direction
relative to the vector and a fifty percent chance that it would be incorporated in a reverse
manner. Because our insert incorporated its own ribosome binding site (RBS) and T7
promoter region, we were not concerned with this direction when performing our cloning
steps. That said, one hundred percent of the clones that we had sequenced revealed
that our insert had inserted backwards.

Because of this, we chose to excise our

SNAPGFP insert and clone it into the pRSETb expression vector.
While we were revisiting our cloning strategy, we decided to move on from our S30
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translations to PURExpress reactions.

As mentioned above, the PURExpress

transcription/translation system is composed of ribosomes and purified transcription and
translation factors. We were attracted to the high yields reported as well as to the ease
of use afforded by using a commercially-available kit; each reaction required the pipetting
of two PURExpress solutions, water, and DNA template as opposed to the fourteen
components of each S30 reactions. We also chose to scale down our translations to the
10 μL scale. Our reasons for this were two-fold: first, the PURExpress reactions cost
around $1/μL. Second, we were anticipating higher yields on smaller-scale reactions.
Indeed, we saw a very high yield of protein on our first PURExpress reaction. (Figure 21)
Because we wanted a fair comparison between the PURExpress system and the S30
extracts, we also ran a 10 μL-scale S30 trial. (Figure 22) As can be seen below, we
found a 200-fold increase in protein production between the PURExpress and S30
reactions. Furthermore, the PURExpress system was easier to use and the results
remained consistent.

After our SNAPGFP construct was cloned into the pRSETb

expression vector, we next confirmed that it would translate well in PURExpress. (Figure
23)

As can be seen, the pRSETb/SNAPGFP construct translated very well in the

PURExpress reaction.
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10 μL reactions with Pure Express system
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Figure 21. Protein yield for a 10 μL PURExpress reaction. Yield with pRSETb/sfGFP
was 2.2 mg/mL. Note that yield remains low for pJET1.2/SNAPGFP.
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Figure 22. Protein yield for a 10 μL S30 translation. Even at this smaller scale, the
S30 extract only yielded 4.1 μg/mL. Reactions were conducted in triplicate.
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Figure 23. SNAPGFP expresses well in pRSETb expression vector but poorly in the
pJET1.2 vector. Protein yield of a 10 μL PURExpress translation of our SNAPGFP
construct in two different vectors. As shown, pRSETb/SNAPGFP yields were not only
higher than pJET1.2/SNAPGFP but also higher than pRSETb/sfGFP.

Having now confirmed the effectiveness of the PURExpress transcription/translation
system, we were ready to begin working towards our goal of using in vitro
compartmentalization to evolve new aaRS for incorporation of ncAAs into protein.
Because in vitro compartmentalization requires our translation system to work in a waterin-oil emulsion, we next tested the production of protein in PURExpress when emulsified.
(Figure 24) Our IVC emulsion oil consisted of: 95% mineral oil, 4.5% Span 80, 0.5%
Tween 80, and 0.1% Triton X-100, as had been used previously in our group. 64 When
performing our IVC experiments, we first stirred this 100 μL oil mixture on ice for five
minutes. Next, our 10 μL reaction mixture was slowly added to the stirring oil. The
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combined phases were allowed to continue stirring on ice for an additional five minutes.
At this point the emulsified solution was transferred to an incubator and the PURExpress
reaction was conducted without shaking.
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Figure 24. PURExpress experiences 100-fold decrease in production when reacted in
an emulsion. A. Protein yield of 10 μL PURExpress translation of pRSETb/SNAPGFP
B. Protein yield of 10 μL PURExpress translation conducted in an emulsion.

We noted a 100-fold decrease in protein production when running our translation in an
emulsion.

Next, we needed to verify that the PURExpress system could produce

detectable amounts of product when translating linear, benzyl guanine-labeled DNA
template in an emulsion. (Figure 25) Here, we saw about a 14-fold reduction in protein
production from the previous test of circular DNA template in an emulsion.
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Figure 25. PURExpress translates a detectable amount of product when using linear,
labeled template in an emulsion. Protein yield of 10 μL reactions when PURExpress
was used to translate linear, benzyl guanine-labeled DNA in an emulsion

At the same time that we were seeing these reductions in translation efficiency for linear,
labeled DNA templates, another group published a paper that had similar goals to our
project.68 In vitro compartmentalization was used to increase the efficiency of a PylS
mutant 1.4-fold. While this paper did achieve our goal of evolving an aaRS through the
use of in vitro compartmentalization, we also saw several indications here that led us to
question the difficulty of our task. First, rather than evolve a new aaRS that incorporated
a new ncAA, this group evolved an existing aaRS to work more efficiently. As our aim
was to incorporate amino acids that differed significantly in structure from native PylS
substrates, we were concerned with the ability of our system to achieve this goal in the
near future.

Second, because this group used FACS sorting they did not need a

genotype-phenotype linker like our SNAP-tag construct.
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This meant that we were

attempting not only to evolve an entirely new synthetase using IVC but we were
attempting to do so in a manner that required even more chemistry to work inside each
droplet.
As we had labored on this project for a number of years at this point we decided that it
was in our best interests to move on to another project.
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Chapter 3: Synthesis of 4-fluorohistidine and use in polyhistidine tags
Properties of fluorohistidine
In addition to the classes of amino acids discussed in Chapter 1, fluorinated amino acids
provide researchers with tools to study protein structure via

19F

NMR,69-73 increase

structural stability,74-78 modify binding behaviour,79,80 and assess protein activity.74,77,81
Some of these fluorinated amino acids can be seen in figure 26. Until recently,82 no
naturally-occurring fluorinated amino acid had been identified. Because fluorine is not a
common element in protein makeup, 19F NMR of proteins has no appreciable background
noise.71

Furthermore the isotopic abundance of

19F

is 100%, allowing for NMR

experiments conducted on samples of lower concentration than would be practical in

13C

experiments.71 Finally, the chemical shift of fluorine is highly sensitive to environmental
effects as it is determined by the unpaired electrons of fluorine.71
Incorporation of multi-fluorinated amino acids has been shown to increase proteolytic
stability of proteins, particularly when these fluorinated amino acids are incorporated into
helical regions.74-78 This increased stability could in theory increase stability and therefore
decrease dose of insulin and other biologics such as those used to treat autoimmune
conditions.
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Figure 26. Fluorinated amino acids. The structures of trifluoroleucine 8, 4fluorothreonine 9, 4-fluorophenylalanine 10, and meta-fluorotyrosine 11 are shown.
In addition to the above benefits of the incorporation of fluorinated amino acids in general,
the fluorinated histidines, 2-fluorohistidine and 4-fluorohistidine, have another advantage:
they can be used as pH probes.81,83,84 Histidine is unique among the 20 canonical amino
acids in that its side chain pKa of 6 allows for it to be found in both protonated and
deprotonated form at physiological pH. Histidine is present in approximately 50% of
enzyme active sites,85 likely due in part to its ability to serve as both acid and base.
Because the van der Waals radius of fluorine is only slightly larger than that of hydrogen86,
fluorohistidines can be considered isosteric with histidine. While the size of the molecule
is not substantially altered, the electronics of the two systems (fluorohistidine vs. histidine)
are changed. Addition of the electronegative fluorine to system lowers the pK a from 6.0
for histidine to 1.7687 for 4-fluorohistidine and ~1 for 2-fluorohistidine.84 This reduction in
pKa allows for elucidation of histidine’s role in protein function 88, manipulation of protein
function at variable pH89, and, as we demonstrate here, affinity chromatography at
lowered pH.
The Hexahistidine tag is one of the most ubiquitous methods of protein and peptide
purification. With the small size of the hexahistidine tag, high affinity to Ni 2+-NTA resin,
low cost, and use of easily-regenerated resin, capturing recombinantly expressed protein
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with a hexahistidine tag and Ni2+-NTA resin is appealing. For the case of in vitro translated
peptides in a cell-free translation system, however, hexahistidine tags are problematic. In
the Protein Synthesis using Recombinant Elements (PURE) system, E. coli translation
proteins (elongation, initiation, and termination factors, and aminoacyl-tRNA synthetases)
are expressed and purified via a hexahistine tag90. These proteins are combined along
with necessary amino acids, ribosomes, and mRNA to produce peptide 90. Because of
these hexahistidine-tagged proteins in the translation mixure of the PURE system, Ni2+NTA purification of the translation product results in the co-purification of PURE proteins
alongside the desired peptide. These in vitro translated peptides used in downstream
experiments such as binding affinity determination can be compromised by interactions
with unwanted PURE proteins. Orthogonal affinity tags such as GST and FLAG are
available91,92; however, these are less ideal for the PURE system because of GST’s large
size (25 kDa) and FLAG-tag’s low translatability and high cost of Anti-FLAG affinity resin.
Current synthesis of 4-fluorohistidine
In 1973, Kirk and Cohen published two synthetic schemes for the synthesis of 4fluorohistidine. The first15 can be seen in scheme 1. Here we begin with N-acetyl4-nitrohistidine 12.

After esterifying the free carboxyl group, reduction and

conversion to the fluorinated product 14 is achieved in a one-pot synthesis,
followed by deprotection to yield the (+/-) amino acid 15. In scheme 2,14 we begin
with 4-aminoimidazole-5-carboxyamide 16 which is first protected and modified to
its 4-fluoro product 18. Next the ester group is reduced to an alcohol and converted
to an alkly chloride 20 for activation to enolate attack. Subsequent hydrolysis (and
beta decarboxylation) produces the (+/-) amino acid 15.
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Scheme 2

Scheme 1

In both of the Kirk and Cohen papers 14,15, characterization of the intermediate
compounds included neither mass spectra nor nuclear magnetic resonance
spectra. In addition, the limited depth of the experimental writeup motivated us to
elaborate here on each synthetic step to aid in the reproducibility of this work.
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Results

Optimized synthesis of 4-fluorohistidine
As scheme 1 could be completed in fewer steps, our first attempts in this project were to
attempt to reproduce this synthesis.

While N-acetylhistidine is readily available

commercially, N-acetyl-4-nitrohistidine 12 was not readily available. As such, the first
step in our synthesis was nitration of N-acetylhistidine using methods described
previously93. Initial attempts at workup proved challenging. The literature described
recrystallization of the product in water (pH=2) but the N-acetyl-4-fluorohistidine 12 was
highly soluble at this pH. Multiple recrystallizations at pH=5 yielded modest results and
we were able to move forward with the one-pot reduction-diazotation-fluorination trials.
These reactions proved unsuccessful in our hands.
After many attempts to reproduce Scheme 2, we began to work with Scheme 1. 4aminoimidazole-5-carboxyamide 16 was esterified with ethanol and methane sulfonic
acid to give ethyl 4-aminoimidazole-5-carboxylate 17 in yield of 36% after 3 days of reflux.
Previous authors14 allowed this reaction to reflux for 18-21 days, but in our hands returns
began to near zero yield after the three-day mark. Solvent was removed in vacuo and
after neutralization the product was extracted into ethyl acetate.

The product was

characterized by mass spectrometry, proton NMR, and carbon NMR. (Appendix)
The Balz-Scheimann reaction was conducted next. Conversion of 17 to 18 proved
successful. Diazotation was conducted in 50% HBF4/H2O at -10º C. Sodium nitrite in
water was slowly added until the solution turned a blue-green color. The reaction mixture
was next poured into a shallow crystallization dish and irradiated with a medium-
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wavelength UV lamp overnight. The blue-green color faded to a pale yellow during this
time and bubbles of nitrogen were observed. (Figure 27) Upon neutralization to pH 7 with
concentrated NaOH, product 18 was isolated in near-quantitative yields of near-white
powder. Product was characterized by mass spectrometry, proton NMR, carbon NMR,
and fluorine NMR.

Figure 27. Color change allows for visual monitoring of the photochemical BalzScheimann reaction. a) formation of diazonium is indicated by blue-green color b)
reaction is irradiated with a handheld 302 nm lamp c) Upon completion of the reaction,
the solution becomes nearly colorless

After several successful reactions, these Balz-Schiemann reactions began to fail. After
neutralization, the reaction mixture was a deep red color and after extraction the product
was orange (figure 28)

After purification on silica gel, yields had dropped from near-

quantitative to below 20%. When all chemical reagents (17, 50% HBF4/H2O, NaNO2)
were eliminated as problematic, we replaced the one physical “reagent:” light.
Replacement of the bulb in our handheld UV-lamp resulted in a return to near-quantitative
yields with no further purification needed.
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Figure 28. 302 nm lamp failure can be assessed
by visual inspection of reaction product. BalzSchieman product on the left after a successful
reaction. The orange powder on the right is the
result of a reaction run with a lamp which is not
emitting sufficient light at 302 nm.
When monitored via TLC (mobile phase= 5:1:1 EtOAc:MeOH:NH3 (aq)), reduction of the
ester group of 18 to an hydroxyl appeared to also go to completion. Isolation of this
reaction in high yields proved challenging. Upon decomposition of the hydride with water,
a white precipitate formed. This precipitate was repeatedly boiled in methanol and after
vacuum filtration the filtrate was combined with that of the previous filtration. Solvent was
removed in vacuo.

Dissolution in ethyl acetate yielded product of sufficient purity for

characterization, in yields of approximately 65%.

The literature14 indicated that

purification of 19 was not necessary for successful completion of subsequent steps, so
for preparative reactions dissolution in ethyl acetate was not performed. Product was
characterized by mass spectrometry, proton NMR, carbon NMR, and fluorine NMR.
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In place of the chlorination step described in scheme 1 14, we opted to brominate our
compound (Scheme 3) as the reaction conditions for the chlorination used large quantities
of thionyl chloride. While our chosen reagent, phosphorus tribromide, is no less toxic we
were able to reduce the quantity of the active reagent, thus limiting exposure.
Furthermore, we found that the higher reactivity of the bromide leaving group resulted in
greater reproducibility in subsequent steps.

Because of the high reactivity of this

brominated compound 22, no attempts at characterization were made. Next, a malonate
ester synthesis was performed to produce diethyl acetomido-(4-fluoroimidazol-5yl)methyl malonate 21. After column chromatography, the product was characterized by
mass spectrometry, proton NMR, carbon NMR, and fluorine NMR.
Last, the malonate ester was hydrolyzed in aqueous HCl to give free DL-4-fluorohistidine
15. The product was characterized by mass spectrometry, proton NMR, carbon NMR,
and fluorine NMR.

Scheme 3. Optimized synthesis of 4-fluorohistidine. Our optimized synthesis of 4fluorohistidine includes greater detail in the experimental, further characterization of
intermediate compounds, and a bromination in place of chlorination.
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4-Fluorohistidine is a substrate for in vitro translation
With pure 4-Fluorohistidine (HF) in hand we first verified that HF

is a

substrate for wild type histidine-tRNA ligase (HisRS) by using a charging assay
based on MALDI. HisRS readily accepted H F as a substrate, charging it charged
tRNAHis (Figure 26A and B). Next we attempted to incorporate HF into an mRNA
template containing an encoded hexa-histidine tag (MHHHHHHMVEP) by
excluding histidine in a cell-free translation system and replacing it with H F. We
were pleasantly surprised to find that the translation apparatus tolerates the
addition of six sequential HF residues (Figure 29C). HF translates with good fidelity,
as measured by MALDI-TOF (Figure 29C), and good yield, as measured by

35S-

Methionine incorporation (Figure 29D). From the MALDI-TOF data, we observed a
major peak corresponding to a full hexa-fluorohistidine tag being produced, along
with a minor secondary peak corresponding to a peptide containing five H F
residues along with one histidine. This small contamination likely arose from a
small amount of residual histidine present in the PURE reconstituted translation
system.
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Figure 29. 4-Fluorohistidine is compatible with in vitro translation A) MALDI-TOF
aminoacyl-tRNA synthetase assay (AARS) with HisRS but with no added 4-FluoroHis.
B) MALDI-TOF AARS assay with HisRS and 4-FluoroHis. M+ Calcd. 911.2738 Obsd.
911.2710. C) In vitro translated reaction with templated encoding the peptide
MHF6MVEP in the presence of 4-FluoroHis. The major peak corresponds to six
fluorohistidine incorporations: (M – H)- Calcd 1562.5394, Obsd 1561.8245, minor
peak five fluorohistidines and one histidine (M – H)- Calcd 1544.5488, Obsd
1543.8708. D) Translation yield in pmols for 50 mL translation reactions containing
either 100 μM Histidine or 600 μM 4-fluorohistidine. Experiments were performed in
triplicate. Error bars represent the standard deviation from the mean.
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Selective capture of Fluorohis-tagged peptides in the presence of his-tagged
proteins
Based on its lowered pKa, we expected that H F6 tagged peptides would retain
binding to Ni-NTA resin at low pH.

To test this, we quenched in vitro translation

reactions with 10 volumes of binding buffer adjusted to pH values between 8.0 and
3.0. Quenched reactions were bound to Ni-NTA resin, washed three times with
buffer of the same pH, and finally were eluted with 1% TFA. Five
Hexafluorohistidine labeled peptides of different sizes were retained on Ni-NTA
resin at the lowest pH tested (pH=3) (Figure 30A).
Within the PURE translation system used in these experiments, there are 30
individual His-tagged proteins. We measured total His-tagged protein captured and
eluted using a Bradford assay using the same binding/wash pH range used for the
peptides (Figure 30B). We observed that, indeed, most of the protein binding was
lost at lower pH values. At pH of 3.0 the protein concentration was at background
levels. SDS- PAGE analysis showed the identical trend (Figure 30C). Therefore,
at low pH, hexa-fluorohis-tagged peptides can be selectively captured and eluted
on Ni-NTA resin in the presence of his-tagged proteins.
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Figure 30. Protein and peptide elution vs binding/wash pH. (A) Fluorohis-tagged
peptides MVM(HF)6 (X), M(HF)6MVEP (◼), M(HF)6MVLT (●), M(HF)6MVAAAVEP (◆),
MVTNSFVCTSVCGGG(HF)6 (▲),were bound and washed on Ni-NTA resin with
various pH buffers. Peptides were eluted with 1% TFA and were quantified by
scintillation counting of the 35S-Met. Counts were relative to the experiment at pH = 8.
(B) Capture of PURE system His-tagged proteins as a function of pH Buffers were
the same as in (A). 1% TFA was used for elution, and the protein concentration at
each pH quantified by a Bradford Assay. Counts were relative to the experiment at
pH = 8. (C) Coommassie-stained SDS-PAGE gel showing the capture of His-tagged
PURE system proteins as a function of pH.
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Conclusions
In this work we have demonstrated that 4-fluorohistidine is not only a good
substrate for protein biosynthesis, but that peptides containing the six sequential
4-fluorohistidines can be produced in vitro. Moreover, this tag can be used for
selective enrichment of peptides in the presence of many other his-tagged proteins.
Finally, the revised synthesis of 4-fluorohistidine presented here should enable the
use of this unnatural amino acid in other biochemical experiments. Further work
for our group includes work on genetically-encoding 4-fluorohistidine into proteins.
Current experiments indicate that we have successfully incorporated 4fluorohistidine into sfGFP through the use of a PylS mutant. We next intend to
incorporate the amino acid into ubiquitin in order to directly address the pHdependence of a conformational change of K48-linked di-ubiquitin.

Experimental
Ethyl 4-amino-1H-imidazole-5-carboxylate (17)
32.3136 g (198.7 mmol) 4-amino-1H-imidazole-5-carboxamide (16) was was suspended
in 360 mL dry ethanol. 102 mL methane sulfonic acid was added and the reaction was
stirred at reflux for 3 days.

Reaction progress was monitored via thin layer

chromatography (mobile phase=4:1:1 N-butanol:acetic acid: water, Rf=0.64) Solvent was
removed in vacuo and the residual syrup was taken up in approximatedly 200 mL water.
The solution was neutralized with cold, saturated NaOH and extracted 3x into 100 mL
ethyl acetate to yield 10.4798 g (32.4% yield) as a grey-green powder. Further purification
was not performed.
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NMR (300 MHz, DMSO-d6): δ=12.05 (s, 1H), 7,36 (s, 1H), 5.46 (s, 1H), 4.22-4.15 (q,

1H

2H), 1.28-1.23 (t, 3H)
13C

NMR (75 MHz, DMSO-d6): δ=160.98, 152.55, 135.22, 101.11, 58.76, 14.62.

DART (TOF): M/Z calculated for C6H9N3O2 [M+H]+: 156.0695, found: 156.0657

Ethyl 4-fluoro-1H-imidazole-5-carboxylate (18)
583.7 mg (3.762 mmol) of 17 was dissolved in 20 mL 50% HBF4 in water. The solution
was cooled to -10º C. 1.2 g of sodium nitrite was dissolved in approximately 1.5 mL of
water. The nitrite solution was added dropwise to the chilled ethyl 4-amino-1H-imidazole5-carboxylate.

The solution turned blue-green.

Next, the reaction mixture was

transferred to a shallow dish and irradiated overnight with a handheld 302 nm UV light.
The light was held approximately 1 cm away from the surface of the reaction mixture by
placing the light on a ring stand. Irradiation occurred 12-16 hours, until the solution turned
a pale yellow and bubbles were no longer produced.

To monitor via thin layer

chromatography, small aliquots of the reaction mixture were removed and neutralized
before running in 3:1 ethyl acetate: hexanes (Rf=0.56). The solution was stirred on ice
and neutralized with cold, concentrated NaOH and extracted 3 times into 50 mL ethyl
acetate to yield 597.2 mg (100.3 % yield). Further purification was not performed.
1H

NMR (300 MHz, DMSO-d6): δ=13.25 (s, 1H), 7.64 (s, 1H), 4.30-4.23 (q, 2H), 1.30-1.25

(t, 3H)
13C

NMR (75 MHz, DMSO-d6): δ=161.44, 159.96, 156.64, 133.15, 61.13, 15.08

19F

NMR (282 MHz, DMSO-d6): δ=-121.28
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DART (TOF): M/Z calculated for C6H7FN2O2 [M+H]+: 159.0492, found 159.0340

(4-fluoro-1H-imidazol-5-yl) methanol (19)
354.9 mg LiAlH4 (9.352 mmol) was dissolved in 10 mL cold Et2O. 211.3 mg ethyl 4-fluoro1H-imidazole-5-carboxylate (18) (1.336 mmol) was added in 50 mg portions.
Disappearance of the ethyl 4-fluoro-1H-imidazole-5-carboxylate was observed via thin
layer chromatography immediately upon addition (mobile phase=3:1 ethyl acetate:
hexanes. Rfstarting material=0.55. Rfproduct=0.00, product visualized with Pauly reagent. Upon
confirmation of the disappearance of compound IV, a second thin layer chromatography
experiment was run in 5:1:1 ethyl acetate:methanol:NH3 (aq). Rfproduct=0.62) The reaction
was allowed to stir on ice for an additional ten minutes. The reaction was quenched
through the very slow addition of cold water. The precipitate was removed via vacuum
filtration and the filtrate was reserved. The solid was boiled in methanol and vacuum
filtered again. Both filtrates were combined and solvent was removed in vacuo. Ethyl
acetate was added to this crude solid to dissolve the product leaving inorganic impurities
behind. Removal of ethyl acetate in vacuo yielded 68.9 mg (44.1%). This dissolution in
ethyl acetate was not necessary to continue on to the next step, though it was necessary
for characterization and yield calculations. For subsequent reactions, this step was not
performed.
1H

NMR: (400 MHz, DMSO-d6) δ=12.16 (s, 1H), 7.25 (s, 1H), 5.10-5.07 (t, 1H) 4.34-4.32

(d, 2H)
13C

NMR: (101 MHz, DMSO-d6) δ=154.21, 151.94, 128.30, 51.05

ESI: M/Z calculated for C4H5FN2O [M+H]+: 117.0386, found 117.0446
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5-bromomethyl-4-fluoro-1H-imidazole (22)

358.3 mg (3.088 mmol) (4-fluoro-1Himidazol-5-yl) methanol (19) was dissolved in 50 mL
methylene chloride. 880 μL (9.263 mmol) PBr3 was added and the solution was stirred
for eight hours at room temperature. Solvent and excess PBr3 was removed in vacuo to
yield a yellow, glassy film (Note: solid sodium bicarbonate was added to the collection
flask of the rotary evaporator prior to evaporation. This allowed for neutralization of the
acidic solution).

Due to the reactivity of the product, no attempt at purification or

characterization was made.

Diethyl-2-acetamido-2-((4-fluoro-1H-imidazol-5-yl)-methyl)-malonate (21)
1.14 g (16.70 mmol) sodium ethoxide was dissolved in cold, dry ethanol. Diethyl-2acetomidomalonate (1.2 g, 5.525 mol) was added. The solution was poured into a flask
containing crude 5-bromomethyl-4-fluoro-1H-imidazole (22) and stirred for four hours at
room temperature. Solvent was removed in vacuo. Reaction mixture was taken up in
approximately 200 mL water and extracted into 3 times into 100 mL portions of ethyl
acetate. Silica gel column chromatography was performed, first by washing the malonate
ester with ethyl acetate and then eluting with 5% methanol in ethyl acetate as the mobile
phase, yielding 290.6 mg (0.9217 mmol) diethyl-2-acetamido-2-((4-fluoro-1H-imidazol-5yl)-methyl)-malonate (21). (Rf=0.26)
1H

NMR: (400 MHz, CDCl3) δ= 10.58 (s, 1H), 7.10 (s, 1H), 6.91 (s, 1H), 4.24-4.17 (q, 4H),

3.56 (s, 2H), 1.22-1.20 (m, 9H)
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13C

NMR: (101 MHz, CDCl3) δ=170.43, 167.62, 156.36, 154.05, 101.41, 63.37, 23.20,

14.13
NMR: (376 MHz, CDCl3) δ=-141.75

19F

ESI: M/Z calculated for C13H18FN3O5 [M+Z]+: 316.1231, found 316.1259

4-fluorohistidine - 15
290.6 mg (0.9217 mmol) diethyl-2-acetamido-2-((4-fluoro-1H-imidazol-5-yl)-methyl)malonate (21) was dissolved in 6N HCl. The solution was heated at reflux for eight hours.
Solvent was removed in vacuo to yield 146.5 mg (91.8%) 4-fluorohistidine (15).
1H

NMR: (400 MHz, D2O) δ= 8.12 (s, 1H), quartet that shows up behind water, 4.30-4.27

(t, 1H), 3.36-3.34 (q, 2H)
13C

NMR: (101 MHz, D2O) δ= 170.62, 149.25, 146.73, 128.59, 51.83, 39.99, 23.00

19F

NMR: (376 MHz, D2O) δ=-146.87

ESI: M/Z calculated for C6H8FN3O2 [M+H]+=174.0601, found 174.0647
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Appendix
Primer sequences
Amplification of sfGFP insert
FWD with BamHI site (CL1040): AAAggatccATGAGCAAAGGC
REV with SalI site (CL1041): ACGCgtcgacTTATTTATACAG

Amplification of SNAP-tag insert
FWD with NdeI site (CL1442):
aaacatatgggtcatcaccatcaccatcacGAATTCGCTATGGACAAAGATTG
REV with BamHI site (CL1437): aaaggatccGGGGGATCCGCCTGCAGGTCCC

Amplification of SNAP-tag insert with stop codon
FWD with NdeI site (CL1443):
aaacatatgggtcatcaccatcaccatcactAgTTCGCTATGGACAAAGATTG
REV with BamHI site (CL1437): aaaggatccGGGGGATCCGCCTGCAGGTCCC

Amplification of sfGFP insert (overlap with SNAP-tag)
FWD (CL1450): gggtctgggacctgcaggcggatcccccgggATGAGCAAAGGCGAAGAA
REV (CL1451): GGTTATGCTAGTTATTGCTCAGCTTATTTATACAGTTCATCC

Amplification of SNAP-tag insert (overlap with sfGFP)
FWD (CL1448):
CGGTTTAAACCGGGGATCTCGATAATACGACTCACTATAGGatctagaagaaggagatataa
aacatatgggtcatcacc
REV (CL1449): cccgggggatccgcctgcaggtcccagaccc

Labeling of SNAPGFP fusion protein with benzyl guanine
FWD (CL1432): [AminoC6]CGGTTTAAACCGGGGATCTCGA
REV (CL1433): [AminoC6]GGTTATGCTAGTTATTGCTCAGC
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Insertion of stop codon into SNAPGFP sequence
TAG1 FWD (CL1594): ccatcacTAGTTCGCTATGG
REV (CL1595): CCATAGCGAACTAgtgatgg

TAG1 FWD ALTERNATE (CL1717): ccatcacTAGTTCGCTATGGACAAAGATTGcg
REV

(CL1718): CGCAATCTTTGTCCATAGCGAACTAGTGATGG

TAG2 FWD (CL1596): ccatcacGAATAGGCTATGG
REV (CL1597): CCATAGCCTATTCgtgatgg

TAG2 FWD ALTERNATE (CL1719): ccatcacGAATAGGCTATGGACAAAGATTGcg
REV

(CL1720): CGCAATCTTTGTCCATAGCCTATTCGTGATGG

TAG3 FWD (CL1598): ccatcacGAAttcTAGATGG
REV (CL1599): CCATCTAgaaTTCgtgatgg

TAG3 FWD ALTERNATE (CL1721): ccatcacGAATTCTAGATGGACAAAGATTGcg
REV

(CL1722): CGCAATCTTTGTCCATCTAGAATTCGTGATGG

TAG4 FWD (CL1672): CGCTtagGACAAAGATTGcg
REV (CL1673): CGCAATCTTTGTCCTAAGCG

TAG5 FWD (CL1674): CGCTATGtagAAAGATTGcg
REV (CL1677): CGCAATCTTTCTACATAGCG

TAG6 FWD (CL1678): CGCTATGGACtagGATTGcg
REV (CL1679): CGCAATCCTAGTCCATAGCG
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TAG7 FWD (CL1680): ggttaaaTAGggcgaagtgattagctatcagc
REV (CL1681): GCTGATAGCTAATCACTTCGCCCTATTTAACC

TAG8 FWD (CL1682): ggttaaatttTAGgaagtgattagctatcagc
REV (CL1683): GCTGATAGCTAATCACTTCCTAAAATTTAACC

TAG9 FWD (CL1684): ggttaaatttggcgaaTAGattagctatcagc
REV (CL1685): GCTGATAGCTAATCTATTCGCCAAATTTAACC

TAG10 FWD (CL1686): ggttaaatttggcgaagtgTAGagctatcagc
REV (CL1687): GCTGATAGCTCTACACTTCGCCAAATTTAACC

Amplification of SNAPGFP_SUPSER
FWD (CL1513): GGATCTCGATAATACGACTCACTATAGGatctagaagaagg
REV (CL1714): TATAAAGCTTTATACCTGGCGGAGAGAGGGGGATTTGAACCCCCG

Removal of N-terminal polyhistidine tag from SNAPGFP and addition of C-terminal tag
FWD (CL1780): atatattctagaGAATT CGCTATGGACAAAGATTGcg
REV (CL1781):
ATATATAAGCTTGTGATGGTGATGGTGATGTTATTTATACAGTTCATCCATGC

Addition of serine suppressor to SNAPGFP (C-term His)
FWD (CL1780): atatattctagaGAATTCGCTATGGACAAAGATTGcg
REV1 (CL1782):
CCGCTCCGGCATCTCTCCCCTATAGTGAGTCGTATTAGTGATGGTGATGGTGATGT
TATTTATACAGTTCATCC
REV2 (CL1783):
TGGCGGAGAGAGGGGGATTTGAACCCCCGGTAGAGTTGCCCCTACTCCGGTTTTA
GAGACCGGTCCGTTCAG
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DNA Sequences
pRSET/sfGFP64

The ORF for sfGFP is highlighted in red (including an N-terminal His tag and upstream
fusion peptide). The coding region of sfGFP starts from the shaded ATG codon.
Ribosome binding site is shown in green. Xba I, Nhe I and Hind III sites are underlined.

GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCAT
CATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCA
TGATGAGCAAAGGCGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTGGAACT
GGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAGGGCGA
TGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAACTGCCG
GTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTTAGCC
GTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTGAAGG
CTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGACCCGT
GCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAGGGCA
TCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACTTCAA
CAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGCCAAC
TTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCATTATC
AACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTACTTG
AGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATGGTG
CTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGTATAA
ATAAAAGCTTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCT
GCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGA
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GGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGGCGTAATAGCGAAGAG
GCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGAC
GCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTG
ACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTT
TCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTA
GGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGA
TGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGG
AGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTA
TCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAA
AAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTAC
AATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTC
TAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAA
TAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCC
TTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTA
AAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCA
ACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGC
ACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGA
GCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAG
TCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCC
ATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACC
GAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATC
GTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGAT
GCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTC
TAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACC
ACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCC
GGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC
TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA
ATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGAC
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGAT
CTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTC
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTT
TTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTG
GTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAG
CAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACT
TCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTG
GCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGT
TACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCA
GCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGA
AAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAG
GGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCT
TTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCT
CGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGT
TCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATT
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CTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCG
AACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACG
CAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAG

pJET1.2/SNAPGFP

The ORF for SNAPGFP is highlighted in red. Ribosome binding site in green.
ATCTTTCTAGAAGATCTCCTACAATATTCTCAGCTGCCATGGAAAATCGATGTTCTT
CTTTTATTCTCTCAAGATTTTCAGGCTGTATATTAAAACTTATATTAAGAACTATGCT
AACCACCTCATCAGGAACCGTTGTAGGTGGCGTGGGTTTTCTTGGCAATCGACTCT
CATGAAAACTACGAGCTAAATATTCAATATGTTCCTCTTGACCAACTTTATTCTGCAT
TTTTTTTGAACGAGGTTTAGAGCAAGCTTCAGGAAACTGAGACAGGAATTTTATTAA
AAATTTAAATTTTGAAGAAAGTTCAGGGTTAATAGCATCCATTTTTTGCTTTGCAAGT
TCCTCAGCATTCTTAACAAAAGACGTCTCTTTTGACATGTTTAAAGTTTAAACCTCCT
GTGTGAAATTGTTATCCGCTCACAATTCCACACATTATACGAGCCGGAAGCATAAA
GTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCT
CACTGCCAATTGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATC
GGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCG
CTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACT
CAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACAT
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGC
GTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC
AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAG
CTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCC
TTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAG
TTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAG
CCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGAC
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ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTA
TGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGA
AGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGT
TGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTT
GCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTT
TCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCAT
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAA
TCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGT
GAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCC
CGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCA
ATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGC
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCA
GTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGC
GCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATG
GCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTT
GTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGG
CCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGC
CATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAAT
AGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGC
GCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAA
AACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCA
CCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACA
GGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATAC
TCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAG
CGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATT
TCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTA
TAAAAATAGGCGTATCACGAGGCCGCCCCTGCAGCCGAATTATATTATTTTTGCCA
AATAATTTTTAACAAAAGCTCTGAAGTCTTCTTCATTTAAATTCTTAGATGATACTTC
ATCTGGAAAATTGTCCCAATTAGTAGCATCACGCTGTGAGTAAGTTCTAAACCATTT
TTTTATTGTTGTATTATCTCTAATCTTACTACTCGATGAGTTTTCGGTATTATCTCTAT
TTTTAACTTGGAGCAGGTTCCATTCATTGTTTTTTTCATCATAGTGAATAAAATCAAC
TGCTTTAACACTTGTGCCTGAACACCATATCCATCCGGCGTAATACGACTCACTATA
GGGAGAGCGGCCGCCAGATCTTCCGGATGGCTCGAGTTTTTCAGCAAGAT TTATTTA
TACAGTTCATCCATGCCATGTGTAATGCCCGCAGCGGTCACAAATTCCAGCAGCACCATGTGATCCCGTTTCTCATT
CGGGTCCTTGCTCAGCACGCTCTGGGTGCTCAAGTAATGATTATCCGGCAGAAGCACGGGACCGTCGCCAATGGGGG
TATTCTGTTGATAATGATCCGCCAGCTGAACGCTTCCGTCCTCCACATTGTGCCGAATCTTGAAGTTGGCCTTAATG
CCGTTCTTCTGCTTGTCGGCGGTGATGTAGACGTTGTGGCTGTTGAAGTTGTACTCCAGCTTGTGCCCCAGTATGTT
GCCATCCTCTTTGAAGTCGATGCCCTTCAGCTCAATGCGGTTCACCAGGGTATCGCCTTCGAATTTGACCTCCGCAC
GGGTCTTATAGGTGCCGTCATCCTTAAACGAGATCGTCCGTTCCTGAACATAGCCTTCAGGCATGGCGCTTTTGAAG
AAGTCATGCCGCTTCATGTGGTCCGGGTAACGGCTAAAGCATTGCACGCCATACGTCAGGGTGGTGACAAGGGTGGG
CCAAGGAACCGGCAGTTTCCCGGTCGTGCAAATAAACTTCAGGGTCAGTTTGCCATTGGTCGCATCGCCCTCCCCTT
CCCCACGCACGCTAAACTTGTGGCCATTTACATCGCCATCCAGTTCCACCAGAATCGGAACCACGCCGGTAAACAGT
TCTTCTTCTTCGCCTTTGCTCATCCCGGGGGATCCGCCTGCAGGTCCCAGACCCGGTTTACCCAGACGATGACCTTC
ATGGGCCAGCAGCCACTCTTTCACCGCCAGACCACCTTCATAACCGCCAACCGCACCGCTAGAGCTAACCACACGAT
GGCACGGAATCAGAATCGGCACCGGGTTACCGCTCAGCGCGGTTTTAACGGCGGCGGTGGCCGCCGGATTACCCGCC
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AGGGCCGCCAGCTGCTGATAGCTAATCACTTCGCCAAATTTAACCACTTTCAGCAGTTTCCACAGCACCTGACGGGT
AAAGCTCTCCTGCTGAAACACCGGATGATGCAGCGCCGGAACCGGAAATTCTTCAATCGCTTCCGGCTGATGAAAAT
ACGCGTTCAGCCACGCGGTCGCCTGCATCAGCGGTTCCGGACCACCCAGCACGGCGGCCGGGGCCGGAACTTCAACC
GCATCGGCCGCGCTGGTGCCTTTACCCAGCAGTTTAATTTCATGCAGGCCCTGTTCGCAGCCGCTCAGTTCCAGTTT
GCCCAGCGGGCTATCCAGGGTGGTACGTTTCATTTCGCAATCTTTGTCCATAGCGAATTCGTGATGGTGATGGTGAT
GACCCATATGTTTTATATCTCCTTCTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGC
GGGATCGAGATC

pRSETb/SNAPGFP

ORF for SNAPGFP highlighted in red (including an N-terminal His tag.) The coding
region of SNAPGFP starts from the shaded ATG codon. Ribosome binding site is
shown in green. Xba I, BamHI and Hind III sites are underlined.

GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcacGAATTCGCTATGGACAAA
GATTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgaacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaatttccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
cggtaacccggtgccgattc tgattccgtg ccatcgtgtg gttagctcta gcggtgcggt tggcggttatgaaggtggtc
tggcggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccc
cgggATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGG
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TGGAACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGG
AGGGCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAA
ACTGCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGC
TTTAGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGC
CTGAAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAA
GACCCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTG
AAGGGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACA
ACTTCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAA
GGCCAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGAT
CATTATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCA
TTACTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCAC
ATGGTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAAC
TGTATAAATAAGGTATAAAGCTTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCT
GAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTA
AACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGGCGT
AATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATG
GCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTA
CGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTT
CTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGG
GGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTT
GATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCC
CTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAA
CACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGG
CCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAAT
ATTAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTAT
TTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGA
TAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTC
GCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACG
CTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCG
AACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTT
CCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGA
CGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTT
GAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT
ATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAA
CGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGT
AACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAG
CGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTG
GCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGAT
AAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTG
ATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCC
AGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACT
ATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTG
GTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTT
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TAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCT
TAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATC
TTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACC
GCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGG
TAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAG
TTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAAT
CCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGAC
TCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCG
TGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGC
GTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATC
CGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGA
AACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCG
ATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCG
GCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCG
TTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGC
TCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG
AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAG
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pRSETb/SNAPGFP-CtermHis

ORF for SNAPGFP-CtermHis is in red. Restriction sites for XbaI and HindIII are
underlined.
AAGCTTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCA
CCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGG
TTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGGCGTAATAGCGAAGAGGCCC
GCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGC
CCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCG
CTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTC
GCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGT
TCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGT
TCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTC
CACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTC
GGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAAT
GAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTT
AGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAAT
ACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATA
TTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTT
TGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAG
ATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAG
CGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTT
TTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAA
CTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCAC
AGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAA
CCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTT
GGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGC
CTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTA
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GCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCAC
TTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGG
TGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCC
CGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATA
GACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAA
GTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTA
GGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTT
CCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTT
TTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTT
TGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAG
AGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCA
AGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCT
GCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTAC
CGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCT
TGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAG
CGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGT
CGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTA
TAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGT
CAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCT
GGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGT
GGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACG
ACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAA
CCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGGATCTCGATCCCGCGAA
ATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTtctagaGAATTCGCTAT
GGACAAAGATTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcga
acagggcctgcatgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgc
cgtgctgggtggtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaag
aatttccggttccggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtg
gttaaatttggcgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaac
cgcgctgagcggtaacccggtgccgattctgattccgtgccatcgtgtggttagctctagcggtgcggttggcggttatgaag
gtggtctggcggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcgg
atcccccgggATGAGCAAAGGCGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTG
GAACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAG
GGCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAAC
TGCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTT
AGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG
AAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGAC
CCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAG
GGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACT
TCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGC
CAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCAT
TATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTA
CTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATG
GTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGT
ATAAATAACATCACCATCACCATCACAAGctt
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pRSETb/SNAPGFP-TAG1

ORF for SNAPGFP-TAG1 in red. Ribosome binding site in green. Stop codon added
highlighted in green. Sites for HindIII and XbaI underlined.

GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcactagTTCGCTATGGACAAAG
ATTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaattccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
cggtaacccggtgccgattctgattccgtgccatcgtgtggttagctctagcggtgcggttggcggttatgaaggtggtctggc
ggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccccggg
ATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTGG
AACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAGG
GCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAACT
GCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTT
AGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG
AAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGAC
CCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAG
GGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACT
TCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGC
CAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCAT
TATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTA
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CTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATG
GTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGT
ATAAATAAGGTATAAAGCTTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAG
TTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAAC
GGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGGCGTAATA
GCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCG
AATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGC
GCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTT
CCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGG
CTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGA
TTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTT
TGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACA
CTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCC
TATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATAT
TAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTT
GTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATA
AATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGC
CCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCT
GGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAA
CTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCC
AATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACG
CCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGA
GTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTAT
GCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACG
ATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAA
CTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCG
TGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGC
GAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAA
AGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGAT
AAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCA
GATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTA
TGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGG
TAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTA
ATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTA
ACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTT
CTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC
TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTA
ACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTT
AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCC
TGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTC
AAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTG
CACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGT
GAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCG
70

GTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAA
CGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGAT
TTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG
CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGT
TATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCT
CGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGA
GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAG
pRSETb/SNAPGFP-TAG2

ORF for SNAPGFP-TAG2 in red. Ribosome binding site in green. Stop codon
highlighted in green. Restriction sites for Hind III and Xba I underlined.

GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcacgaatagGCTATGGACAAAGA
TTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaattccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
cggtaacccggtgccgattctgattccgtgccatcgtgtggttagctctagcggtgcggttggcggttatgaaggtggtctggc
ggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccccggg
ATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTGG
AACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAGG
GCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAACT
GCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTT
AGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG
AAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGAC
71

CCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAG
GGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACT
TCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGC
CAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCAT
TATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTA
CTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATG
GTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGT
ATAAATAAGGTATAAAGCTTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAG
TTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAAC
GGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGGCGTAATA
GCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCG
AATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGC
GCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTT
CCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGG
CTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGA
TTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTT
TGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACA
CTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCC
TATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATAT
TAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTT
GTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATA
AATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGC
CCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCT
GGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAA
CTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCC
AATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACG
CCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGA
GTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTAT
GCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACG
ATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAA
CTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCG
TGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGC
GAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAA
AGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGAT
AAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCA
GATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTA
TGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGG
TAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTA
ATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTA
ACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTT
CTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC
TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTA
ACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTT
72

AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCC
TGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTC
AAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTG
CACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGT
GAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCG
GTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAA
CGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGAT
TTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG
CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGT
TATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCT
CGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGA
GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAG

pJET1.2/SNAPGFP_SUPSER

ATCTTTCTAGAAGATCTCCTACAATATTCTCAGCTGCCATGGAAAATCGATGTTCTT
CTTTTATTCTCTCAAGATTTTCAGGCTGTATATTAAAACTTATATTAAGAACTATGCT
AACCACCTCATCAGGAACCGTTGTAGGTGGCGTGGGTTTTCTTGGCAATCGACTCT
CATGAAAACTACGAGCTAAATATTCAATATGTTCCTCTTGACCAACTTTATTCTGCAT
TTTTTTTGAACGAGGTTTAGAGCAAGCTTCAGGAAACTGAGACAGGAATTTTATTAA
AAATTTAAATTTTGAAGAAAGTTCAGGGTTAATAGCATCCATTTTTTGCTTTGCAAGT
TCCTCAGCATTCTTAACAAAAGACGTCTCTTTTGACATGTTTAAAGTTTAAACCTCCT
GTGTGAAATTGTTATCCGCTCACAATTCCACACATTATACGAGCCGGAAGCATAAA
GTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCT
CACTGCCAATTGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATC
GGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCG
73

CTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACT
CAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACAT
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGC
GTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC
AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAG
CTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCC
TTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAG
TTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAG
CCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGAC
ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTA
TGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGA
AGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGT
TGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTT
GCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTT
TCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCAT
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAA
TCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGT
GAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCC
CGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCA
ATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGC
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCA
GTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGC
GCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATG
GCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTT
GTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGG
CCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGC
CATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAAT
AGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGC
GCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAA
AACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCA
CCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACA
GGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATAC
TCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAG
CGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATT
TCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTA
TAAAAATAGGCGTATCACGAGGCCGCCCCTGCAGCCGAATTATATTATTTTTGCCA
AATAATTTTTAACAAAAGCTCTGAAGTCTTCTTCATTTAAATTCTTAGATGATACTTC
ATCTGGAAAATTGTCCCAATTAGTAGCATCACGCTGTGAGTAAGTTCTAAACCATTT
TTTTATTGTTGTATTATCTCTAATCTTACTACTCGATGAGTTTTCGGTATTATCTCTAT
TTTTAACTTGGAGCAGGTTCCATTCATTGTTTTTTTCATCATAGTGAATAAAATCAAC
TGCTTTAACACTTGTGCCTGAACACCATATCCATCCGGCGTAATACGACTCACTATA
GGGAGAGCGGCCGCCAGATCTTCCGGATGGCTCGAGTTTTTCAGCAAGAT
TGGCGGAGAGAGGGGGATTTGAACCCCCGGTAGAGTTGCCCCTACTCCGGTTTTA
74

GAGACCGGTCCGTTCAGCCGCTCCGGCATCTCTCCCCTATAGTGAGTCGTATTAG
GTTATGCTAGTTATTGCTCAGCTTATTTATACAGTTCATCCATGCCATGTGTAATGC
CCGCAGCGGTCACAAATTCCAGCAGCACCATGTGATCCCGTTTCTCATTCGGGTC
CTTGCTCAGCACGCTCTGGGTGCTCAAGTAATGATTATCCGGCAGAAGCACGGGA
CCGTCGCCAATGGGGGTATTCTGTTGATAATGATCCGCCAGCTGAACGCTTCCGT
CCTCCACATTGTGCCGAATCTTGAAGTTGGCCTTAATGCCGTTCTTCTGCTTGTCG
GCGGTGATGTAGACGTTGTGGCTGTTGAAGTTGTACTCCAGCTTtaaaaaGTGCCCC
AGTATGTTGCCATCCTCTTTGAAGTCGATGCCCTTCAGCTCAATGCGGTTCACCAG
GGTATCGCCTTCGAATTTGACCTCCGCACGGGTCTTATAGGTGCCGTCATCCTTAA
ACGAGATCGTCCGTTCCTGAACATAGCCTTCAGGCATGGCGCTTTTGAAGAAGTCA
TGCCGCTTCATGTGGTCCGGGTAACGGCTAAAGCATTGCACGCCATACGTCAGGG
TGGTGACAAGGGTGGGCCAAGGAACCGGCAGTTTCCCGGTCGTGCAAATAAACTT
CAGGGTCAGTTTGCCATTGGTCGCATCGCCCTCCCCTTCCCCACGCACGCTAAAC
TTGTGGCCATTTACATCGCCATCCAGTTCCACCAGAATCGGAACCACGCCGGTAAA
CAGTTCTTCTTCTTCGCCTTTGCTCATCCCGGGGGATCCGCCTGCAGGTCCCAGA
CCCGGTTTACCCAGACGATGACCTTCATGGGCCAGCAGCCACTCTTTCACCGCCA
GACCACCTTCATAACCGCCAACCGCACCGCTAGAGCTAACCACACGATGGCACGG
AATCAGAATCGGCACCGGGTTACCGCTCAGCGCGGTTTTAACGGCGGCGGTGGC
CGCCGGATTACCCGCCAGGGCCGCCAGCTGCTGATAGCTAATCACTTCGCCAAAT
TTAACCACTTTCAGCAGTTTCCACAGCACCTGACGGGTAAAGCTCTCCTGCTGAAA
CACCGGATGATGCAGCGCCGGAACCGGAAATTCTTCAATCGCTTCCGGCTGATGA
AAATACGCGTTCAGCCACGCGGTCGCCTGCATCAGCGGTTCCGGACCACCCAGCA
CGGCGGCCGGGGCCGGAACTTCAACCGCATCGGCCGCGCTGGTGCCTTTACCCA
GCAGTTTAATTTCATGCAGGCCCTGTTCGCAGCCGCTCAGTTCCAGTTTGCCCAGC
GGGCTATCCAGGGTGGTACGTTTCATTTCGCAATCTTTGTCCATAGCGAATTCGTG
ATGGTGATGGTGATGACCCATATGTTTTATATCTCCTTCTTCTAGAGGGAAACCGTT
GTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGGGATCGAGATC
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pRSETb/SNAPGFP_SUPSER

ORF for SNAPGFP-SUPSER in red. Ribosome binding site in green.
GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcacGAATTCGCTATGGACAAA
GATTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgaacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaatttccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
cggtaacccggtgccgattctgattccgtgccatcgtgtggttagctctagcggtgcggttggcggttatgaaggtggtctggc
ggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccccggg
ATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTGG
AACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAGG
GCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAACT
GCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTT
AGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG
AAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGAC
CCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAG
GGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACT
TCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGC
CAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCAT
TATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTA
CTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATG
GTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGT
76

ATAAATAAGCTGAGCAATAACTAGCATAACCTAATACGACTCACTATAGGGGAGAG
ATGCCGGAGCGGCTGAACGGACCGGTCTCTAAAACCGGAGTAGGGGCAACTCTA
CCGGGGGTTCAAATCCCCCTCTCTCCGCCAGGTATAAAGCTTGATCCGGCTGCTA
ACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGC
ATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGA
ACTATATCCGGATCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
ACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAG
CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT
AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTC
CCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGG
CACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGC
CCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGA
CTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTAT
AAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAAT
TTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCG
CTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATG
AGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT
GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGG
TGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTT
TTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGC
GCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACT
ATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGAT
GGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGC
GGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATG
AAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAAC
GTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCG
GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA
TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACG
ACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTG
CCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA
TTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAA
TCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCG
TAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT
TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTA
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGT
TCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTA
CATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG
TGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGG
GCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAG
AAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAG
GGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCAC
CTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGA
77

AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCT
CACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGG
CCGATTCATTAATGCAG

pRSETb/SNAPGFP_SUPSER-TAG2

ORF for SNAPGFP-SUPSER in red. Ribosome binding site in green. Stop codon
highlighted in green.
GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcacGAAtagGCTATGGACAAAG
ATTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgaacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaatttccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
cggtaacccggtgccgattctgattccgtgccatcgtgtggttagctctagcggtgcggttggcggttatgaaggtggtctggc
ggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccccggg
ATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTGG
AACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAGG
GCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAACT
GCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTT
AGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG
AAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGAC
CCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAG
GGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACT
TCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGC
CAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCAT
78

TATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTA
CTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATG
GTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGT
ATAAATAAGCTGAGCAATAACTAGCATAACCTAATACGACTCACTATAGGGGAGAG
ATGCCGGAGCGGCTGAACGGACCGGTCTCTAAAACCGGAGTAGGGGCAACTCTA
CCGGGGGTTCAAATCCCCCTCTCTCCGCCAGGTATAAAGCTTGATCCGGCTGCTA
ACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGC
ATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGA
ACTATATCCGGATCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
ACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAG
CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT
AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTC
CCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGG
CACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGC
CCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGA
CTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTAT
AAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAAT
TTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCG
CTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATG
AGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT
GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGG
TGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTT
TTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGC
GCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACT
ATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGAT
GGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGC
GGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATG
AAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAAC
GTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCG
GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA
TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACG
ACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTG
CCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA
TTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAA
TCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCG
TAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT
TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTA
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGT
TCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTA
CATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG
TGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGG
GCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAG
79

AAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAG
GGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCAC
CTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGA
AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCT
CACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGG
CCGATTCATTAATGCAG

pRSETb/SNAPGRP_SUPSER-TAG3

ORF for SNAPGFP-SUPSER in red. Ribosome binding site in green. Stop codon
highlighted in green.
GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcacGAATTCtagATGGACAAAG
ATTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgaacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaatttccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
cggtaacccggtgccgattctgattccgtgccatcgtgtggttagctctagcggtgcggttggcggttatgaaggtggtctggc
ggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccccggg
ATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTGG
AACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAGG
GCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAACT
GCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTT
AGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG
80

AAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGAC
CCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAG
GGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACT
TCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGC
CAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCAT
TATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTA
CTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATG
GTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGT
ATAAATAAGCTGAGCAATAACTAGCATAACCTAATACGACTCACTATAGGGGAGAG
ATGCCGGAGCGGCTGAACGGACCGGTCTCTAAAACCGGAGTAGGGGCAACTCTA
CCGGGGGTTCAAATCCCCCTCTCTCCGCCAGGTATAAAGCTTGATCCGGCTGCTA
ACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGC
ATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGA
ACTATATCCGGATCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
ACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAG
CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT
AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTC
CCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGG
CACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGC
CCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGA
CTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTAT
AAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAAT
TTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCG
CTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATG
AGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT
GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGG
TGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTT
TTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGC
GCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACT
ATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGAT
GGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGC
GGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATG
AAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAAC
GTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCG
GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA
TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACG
ACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTG
CCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA
TTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAA
TCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCG
TAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT
TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTA
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGT
81

TCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTA
CATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG
TGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGG
GCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAG
AAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAG
GGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCAC
CTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGA
AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCT
CACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGG
CCGATTCATTAATGCAG

pRSETb/SNAPGFP_SUPSER-TAG8

ORF for SNAPGFP-SUPSER in red. Ribosome binding site in green. Stop codon
highlighted in green.
GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcacGAATTCGCTATGGACAAA
GATtaggaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgaacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaatttccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
82

cggtaacccggtgccgattctgattccgtgccatcgtgtggttagctctagcggtgcggttggcggttatgaaggtggtctggc
ggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccccggg
ATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGGTGG
AACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGGAGG
GCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAAACT
GCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGCTTT
AGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG
AAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAAGAC
CCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTGAAG
GGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACAACT
TCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAAGGC
CAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGATCAT
TATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCATTA
CTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCACATG
GTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAACTGT
ATAAATAAGCTGAGCAATAACTAGCATAACCTAATACGACTCACTATAGGGGAGAG
ATGCCGGAGCGGCTGAACGGACCGGTCTCTAAAACCGGAGTAGGGGCAACTCTA
CCGGGGGTTCAAATCCCCCTCTCTCCGCCAGGTATAAAGCTTGATCCGGCTGCTA
ACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGC
ATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGA
ACTATATCCGGATCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
ACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAG
CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT
AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTC
CCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGG
CACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGC
CCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGA
CTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTAT
AAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAAT
TTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCG
CTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATG
AGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT
GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGG
TGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTT
TTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGC
GCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACT
ATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGAT
GGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGC
GGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATG
AAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAAC
GTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCG
GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA
TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACG
83

ACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTG
CCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGA
TTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAA
TCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCG
TAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT
TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTA
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGT
TCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTA
CATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG
TGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGG
GCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAG
AAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAG
GGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCAC
CTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGA
AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCT
CACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGG
CCGATTCATTAATGCAG

84

pRSETb/SNAPGFP_PylT

ORF for SNAPGFP in red. Ribosome binding site in green. PylT highlighted in yellow.
GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC
CTCTAGAagaaggagatataaaacatatgggtcatcaccatcaccatcacGAATTCGCTATGGACAAA
GATTGcgaaatgaaacgtaccaccctggatagcccgctgggcaaactggaactgagcggctgcgaacagggcctg
catgaaattaaactgctgggtaaaggcaccagcgcggccgatgcggttgaagttccggccccggccgccgtgctgggtg
gtccggaaccgctgatgcaggcgaccgcgtggctgaacgcgtattttcatcagccggaagcgattgaagaatttccggttc
cggcgctgcatcatccggtgtttcagcaggagagctttacccgtcaggtgctgtggaaactgctgaaagtggttaaatttgg
cgaagtgattagctatcagcagctggcggccctggcgggtaatccggcggccaccgccgccgttaaaaccgcgctgag
cggtaacccggtgccgattc tgattccgtg ccatcgtgtg gttagctcta gcggtgcggt tggcggttatgaaggtggtc
tggcggtgaaagagtggctgctggcccatgaaggtcatcgtctgggtaaaccgggtctgggacctgcaggcggatcccc
cgggATGAGCAAAGGCGAAGAAGAAGAACTGTTTACCGGCGTGGTTCCGATTCTGG
TGGAACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGTGCGTGGGGAAGGGG
AGGGCGATGCGACCAATGGCAAACTGACCCTGAAGTTTATTTGCACGACCGGGAA
ACTGCCGGTTCCTTGGCCCACCCTTGTCACCACCCTGACGTATGGCGTGCAATGC
TTTAGCCGTTACCCGGACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGC
CTGAAGGCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCACCTATAA
GACCCGTGCGGAGGTCAAATTCGAAGGCGATACCCTGGTGAACCGCATTGAGCTG
AAGGGCATCGACTTCAAAGAGGATGGCAACATACTGGGGCACAAGCTGGAGTACA
ACTTCAACAGCCACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATTAA
GGCCAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGCGTTCAGCTGGCGGAT
CATTATCAACAGAATACCCCCATTGGCGACGGTCCCGTGCTTCTGCCGGATAATCA
TTACTTGAGCACCCAGAGCGTGCTGAGCAAGGACCCGAATGAGAAACGGGATCAC
ATGGTGCTGCTGGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGAAC
85

TGTATAAATAAGCTGAGCAATAACTAGCATAACCTAATACGACTCACTATAGGGGG
AACCTGATCATGTAGATCGAATGGACTCTAAATCCGTTCAGCCGGGTTAGATTCCC
GGGGTTTCCGCCAGGTATAAAGCTTGATCCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCT
CTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGGC
GTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAA
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGT
TACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCT
TTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCG
GGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAAC
TTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGC
CCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACA
ACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCG
GCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAA
ATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCT
ATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCT
GATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTG
TCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAA
CGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACAT
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTT
TTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTG
ACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGT
TGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAAT
TATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACA
ACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATG
TAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGA
GCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACT
GGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGG
ATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCT
GATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGG
CCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAA
CTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCAT
TGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATT
TTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCC
CTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGA
TCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCA
CCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAA
GGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGT
AGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA
ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGG
ACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTT
CGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACA
GCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTA
TCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGG
GAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGT
CGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACG
86

CGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTG
CGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACC
GCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGA
AGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGC
AG
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Compound Characterization
Ethyl 4-aminoimidizol-5-carboxylate 17

C:\Program Files\TSSPro 3.0\Results\Turner\160524\160524 Cropp Scan_415-463.txt

156.0657

100

20000

184.0979

50

10000

212.1308

0

0

50

86

122

158
m/z

Figure S1. Mass spectrum of ethyl 4-aminoimidazol-5-carboxylate 17

88

194

230

Abs. abundance

Rel. Intensity %

30000

Figure S2. Proton NMR of ethyl 4-aminoimidazol-5-carboxylate 17
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Figure S3. Carbon NMR of ethyl 4-aminoimidazol-5-carboxylate 17
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Ethyl 4-fluoroimidazol-5-carboxylate 18
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Figure S4. Mass spectrum of ethyl 4-fluoroimidazol-5-carboxylate 18

Figure S5. Proton NMR of ethyl 4-fluoroimidazol-5-carboxylate 18
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Figure S6. Carbon NMR of ethyl 4-fluoroimidazol-5-carboxylate 18
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Figure S7. Fluorine NMR of ethyl 4-fluoroimidazol-5-carboxylate 18
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(4-fluoroimidazol-5-yl)-methanol 19
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Figure S8. Mass spectrum of (4-fluoroimidazol-5-yl)-methanol 19
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Figure S9. Proton NMR of (4-fluoroimidazol-5-yl)-methanol 19
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Figure S10. Carbon NMR of (4-fluoroimidazol-5-yl)-methanol 19
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Figure S11. Fluorine NMR of (4-fluoroimidazol-5-yl)-methanol 19
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Diethyl-2-acetamido-2-((4-fluoroimidazol-5-yl)-methyl)-malonate 21

r1701137r01 #1-50 RT: 0.00-0.36 AV: 50 NL: 2.81E7
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Figure S12. Mass spectrum of diethyl 2-acetamido-2-((4-fluoroimidazol-5-yl)-methyl)malonate 21
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Figure S13. Proton NMR of diethyl 2-acetamido-2-((4-fluoroimidazol-5-yl)-methyl)malonate 21
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Figure S14. Carbon NMR of diethyl 2-acetamido-2-((4-fluoroimidazol-5-yl)-methyl)malonate 21
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Figure S15. Fluorine NMR of diethyl 2-acetamido-2-((4-fluoroimidazol-5-yl)-methyl)malonate 21
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4-fluorohistidine 15
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Figure S16. Mass spectrum of 4-fluorohistidine 15
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Figure S17. Proton NMR of 4-fluorohistidine 15
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Figure S17. Carbon NMR of 4-fluorohistidine 15
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Figure S18. Fluorine NMR of 4-fluorohistidine 15
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